PRKCA - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
PLA2G4A	phospholipase A2 group IVA	phospho-PLA2 pathway Acyl chain remodelling of PC Acyl chain remodeling of CL Acyl chain remodelling of PS Acyl chain remodelling of PE Acyl chain remodelling of PI Acyl chain remodelling of PG Hydrolysis of LPC Synthesis of PA Arachidonate metabolism ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL COPI-independent Golgi-to-ER retrograde traffic	Fluticasone propionate Procaine Quinacrine Niflumic acid Darapladib Fluticasone
PLCB1	phospholipase C beta 1	PLC beta mediated events PLC beta mediated events Synthesis of IP3 and IP4 in the cytosol Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (q) signalling events G beta:gamma signalling through PLC beta Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Presynaptic function of Kainate receptors		Early infantile epileptic encephalopathy; Ohtahara syndrome
PLD1	phospholipase D1	Synthesis of PG Synthesis of PA Role of phospholipids in phagocytosis Neutrophil degranulation RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RHOG GTPase cycle	Choline LAX-101 Choline salicylate
PLD2	phospholipase D2	Synthesis of PG Synthesis of PA Role of phospholipids in phagocytosis RAC1 GTPase cycle RAC2 GTPase cycle	Choline Choline salicylate
POLB	DNA polymerase beta	POLB-Dependent Long Patch Base Excision Repair Resolution of AP sites via the multiple-nucleotide patch replacement pathway Resolution of AP sites via the single-nucleotide replacement pathway APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway PCNA-Dependent Long Patch Base Excision Repair Ub-specific processing proteases Abasic sugar-phosphate removal via the single-nucleotide replacement pathway	Cytarabine Iron dATP (1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL Ferrous gluconate Ferrous succinate Ferrous ascorbate Ferrous fumarate Ferrous glycine sulfate
PPARA	peroxisome proliferator activated receptor alpha	BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha SUMOylation of intracellular receptors Cytoprotection by HMOX1 Heme signaling Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	alpha-Linolenic acid Icosapent Troglitazone Valproic acid Indomethacin Rosiglitazone Fenoprofen Clofibrate Fenofibrate Ibuprofen Amiodarone Gemfibrozil Bezafibrate Prasterone N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Flufenamic acid Resveratrol Phthalic Acid Lauric acid Stearic acid Doconexent Palmitic Acid Oleic Acid Caprylic acid Arachidonic Acid Reglitazar Elafibranor Cardarine Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar GW-590735 Indeglitazar Myristic acid Aleglitazar Clinofibrate Ciprofibrate Dexibuprofen Soybean oil Omega-3 fatty acids Myrrh Isoflavone Leukotriene B4 Fenofibric acid Fish oil
PPARG	peroxisome proliferator activated receptor gamma	PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	alpha-Linolenic acid Icosapent Troglitazone Mesalazine Valproic acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Clofazimine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglitazar Elafibranor AMG-131 CLX-0921 Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid 9(S)-HODE difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Cannabidiol Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate Isoflavone Naveglitazar Fenofibric acid Fish oil Medical Cannabis Nabiximols Darglitazone Curcumin sulfate	Thyroid cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Type II diabetes mellitus
PPM1A	protein phosphatase, Mg2+/Mn2+ dependent 1A	Downregulation of SMAD2/3:SMAD4 transcriptional activity Energy dependent regulation of mTOR by LKB1-AMPK
PPP1R14A	protein phosphatase 1 regulatory inhibitor subunit 14A	RHO GTPases activate PKNs
PRKCZ	protein kinase C zeta	GPVI-mediated activation cascade TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) VEGFR2 mediated cell proliferation RHO GTPases Activate NADPH Oxidases Estrogen-stimulated signaling through PRKCZ Estrogen-stimulated signaling through PRKCZ	Tamoxifen Staurosporine Dequalinium Benzoyl peroxide
PRKG1	protein kinase cGMP-dependent 1	Ca2+ pathway
PSMB4	proteasome 20S subunit beta 4	Activation of NF-kappaB in B cells Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha ER-Phagosome pathway ER-Phagosome pathway Cross-presentation of soluble exogenous antigens (endosomes) Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Vpu mediated degradation of CD4 Vif-mediated degradation of APOBEC3G SCF(Skp2)-mediated degradation of p27/p21 Degradation of beta-catenin by the destruction complex Downstream TCR signaling Regulation of activated PAK-2p34 by proteasome mediated degradation Separation of Sister Chromatids FCERI mediated NF-kB activation Autodegradation of the E3 ubiquitin ligase COP1 Regulation of ornithine decarboxylase (ODC) ABC-family proteins mediated transport AUF1 (hnRNP D0) binds and destabilizes mRNA Asymmetric localization of PCP proteins Degradation of AXIN Degradation of DVL Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Dectin-1 mediated noncanonical NF-kB signaling CLEC7A (Dectin-1) signaling Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'on' state Regulation of RAS by GAPs TNFR2 non-canonical NF-kB pathway NIK-->noncanonical NF-kB signaling Defective CFTR causes cystic fibrosis MAPK6/MAPK4 signaling UCH proteinases Ub-specific processing proteases Assembly of the pre-replicative complex Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Ubiquitin-dependent degradation of Cyclin D The role of GTSE1 in G2/M progression after G2 checkpoint FBXL7 down-regulates AURKA during mitotic entry and in early mitosis RUNX1 regulates transcription of genes involved in differentiation of HSCs Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Regulation of RUNX3 expression and activity Regulation of PTEN stability and activity Neddylation Regulation of expression of SLITs and ROBOs Interleukin-1 signaling Negative regulation of NOTCH4 signaling KEAP1-NFE2L2 pathway GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 Degradation of CDH1 Somitogenesis Antigen processing: Ubiquitination & Proteasome degradation Proteasome assembly Proteasome assembly Antigen processing: Ub, ATP-independent proteasomal degradation GSK3B-mediated proteasomal degradation of PD-L1(CD274) SPOP-mediated proteasomal degradation of PD-L1(CD274) AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Degradation of CRY and PER proteins Degradation of CRY and PER proteins Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide	(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
PTGIR	prostaglandin I2 receptor	Prostanoid ligand receptors Prostacyclin signalling through prostacyclin receptor Prostacyclin signalling through prostacyclin receptor G alpha (s) signalling events	Treprostinil Iloprost Dinoprost tromethamine Epoprostenol Beraprost Selexipag
PTPN1	protein tyrosine phosphatase non-receptor type 1	Integrin signaling Negative regulation of MET activity Insulin receptor recycling Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA/IFNB signaling Growth hormone receptor signaling Growth hormone receptor signaling Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid -Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
PTPN11	protein tyrosine phosphatase non-receptor type 11	Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants SARS-CoV-2 activates/modulates innate and adaptive immune responses Co-inhibition by BTLA	Dodecyltrimethylammonium	Metachondromatosis Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
PTPN12	protein tyrosine phosphatase non-receptor type 12	SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling EGFR downregulation Signaling by PDGF Downregulation of ERBB2 signaling Interleukin-37 signaling Constitutive Signaling by Overexpressed ERBB2	Tiludronic acid
PTPN6	protein tyrosine phosphatase non-receptor type 6	GPVI-mediated activation cascade Regulation of KIT signaling Signaling by ALK PECAM1 interactions Co-inhibition by PD-1 Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Nuclear events stimulated by ALK signaling in cancer Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Co-inhibition by BTLA	Tiludronic acid
RAC1	Rac family small GTPase 1	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Translocation of SLC2A4 (GLUT4) to the plasma membrane Nef and signal transduction NRAGE signals death through JNK Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling FCERI mediated MAPK activation CD28 dependent Vav1 pathway EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PCP/CE pathway Sema4D mediated inhibition of cell attachment and migration DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Signal transduction by L1 VEGFR2 mediated vascular permeability RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins RHO GTPases Activate NADPH Oxidases MAPK6/MAPK4 signaling Neutrophil degranulation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 RAC1 GTPase cycle NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Activation of RAC1 downstream of NMDARs FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis WNT5:FZD7-mediated leishmania damping Azathioprine ADME Factors involved in megakaryocyte development and platelet production	Dextromethorphan Azathioprine Guanosine-5'-Diphosphate
RACK1	receptor for activated C kinase 1	Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production Degradation of CDH1	Copper
RAF1	Raf-1 proto-oncogene, serine/threonine kinase	Stimuli-sensing channels Rap1 signalling GP1b-IX-V activation signalling CD209 (DC-SIGN) signaling RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling IFNG signaling activates MAPKs	Sorafenib LErafAON XL281 iCo-007 Cholecystokinin Regorafenib Dabrafenib Fostamatinib

Search Results for: PRKCA